Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 6.69
- Piotroski Score 4.00
- Grade Sector Perform
- Symbol (GRPH)
- Company Graphite Bio, Inc.
- Price $3.18
- Changes Percentage (-2.75%)
- Change -$0.09
- Day Low $3.05
- Day High $3.23
- Year High $29.82
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 03/22/2024
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 03/25/2024
- Fiscal Year End N/A
- Average Stock Price Target $3.50
- High Stock Price Target $7.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$15.33
- Trailing P/E Ratio -0.20743639921722
- Forward P/E Ratio -0.20743639921722
- P/E Growth -0.20743639921722
- Net Income $-124,651,000
